The purpose of this study was to evaluate motor, cognitive, and sensory outcomes of infants <1350 grams enrolled in a randomized double-masked comparison trial of two surfactants (EXO vs INFA) for the treatment of RDS. 95 infants (61.0% follow-up) at 5 centers received Bayley mental and motor scales and an expanded neurological examination at 2 years by assessors masked to neonatal treatment status. Table
At age 2 years, 91.5% of EXO and 93.3% of INFA were free of any cerebral palsy, 16.7% of EXO and 10.6% of INFA had major cognitive impairment (MDI<70). 33.3% of EXO and 36.2% of INFA were at risk (MDI 70-89) for future disabilities.
We conclude that ND outcome at 2 years is not influenced by the choice of either EXO or INFA for RDS prophylaxis. Funded by ONY, Inc., and Forest Laboratories.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rogers, B., Zorn, W., Msall, M. et al. TWO YEAR NEURODEVELOPMENTAL OUTCOME OF INFANTS <1350G ENROLLED IN A MULTICENTER COMPARISON TRIAL OF EXOSURF (EXO) AND INFASURF (INFA) FOR THE TREATMENT OF RDS. 1648. Pediatr Res 39 (Suppl 4), 277 (1996). https://doi.org/10.1203/00006450-199604001-01672
Issue Date:
DOI: https://doi.org/10.1203/00006450-199604001-01672
